Taysha Gene Therapies Quick Ratio 2020-2026 | TSHA
Historical quick ratio values for Taysha Gene Therapies (TSHA) over the last 10 years.
| Taysha Gene Therapies Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2026-06-30 | $0.00B | $0.03B | 0.00 |
| 2026-03-31 | $0.00B | $0.02B | 0.00 |
| 2025-12-31 | $0.00B | $0.03B | 0.00 |
| 2025-09-30 | $0.00B | $0.03B | 0.00 |
| 2025-06-30 | $0.00B | $0.03B | 0.00 |
| 2025-03-31 | $0.00B | $0.02B | 0.00 |
| 2024-12-31 | $0.00B | $0.03B | 0.00 |
| 2024-09-30 | $0.00B | $0.03B | 0.00 |
| 2024-06-30 | $0.00B | $0.03B | 0.00 |
| 2024-03-31 | $0.00B | $0.04B | 0.00 |
| 2023-12-31 | $0.00B | $0.04B | 0.00 |
| 2023-09-30 | $0.00B | $0.18B | 0.00 |
| 2023-06-30 | $0.00B | $0.05B | 0.00 |
| 2023-03-31 | $0.00B | $0.05B | 0.00 |
| 2022-12-31 | $0.00B | $0.06B | 0.00 |
| 2022-09-30 | $0.00B | $0.03B | 0.00 |
| 2022-06-30 | $0.00B | $0.04B | 0.00 |
| 2022-03-31 | $0.00B | $0.05B | 0.00 |
| 2021-12-31 | $0.00B | $0.05B | 0.00 |
| 2021-09-30 | $0.00B | $0.04B | 0.00 |
| 2021-06-30 | $0.00B | $0.03B | 0.00 |
| 2021-03-31 | $0.00B | $0.02B | 0.00 |
| 2020-12-31 | $0.00B | $0.01B | 0.00 |
| 2020-09-30 | $0.00B | $0.01B | 0.00 |
| 2020-06-30 | $0.00B | 0.00 | |
| 2020-03-31 | $0.00B | 0.00 | |
| 2019-12-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.652B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |